For 47% of the nearly 400 food and beverage processors who responded to the annual Food Processing R&D survey, the most important goal for their R&D efforts this year is new product development. Existing product improvement is most important for 17%, and for 14%, cost control is the top priority. Asked to rank concerns as […]
In April, KPMG surveyed 550 financial executives at energy companies. Among respondents, 67% believe that crude oil prices will top $111 per barrel this year. For 55% of respondents, regulatory issues will be their primary challenge this year, and for 43%, they will be the biggest factor affecting capital spending decisions. Sixty-seven percent expect capital […]
In 2010, Pharmaceutical Research and Manufacturers of America (PhRMA) members spending on R&D grew 6.5% to $49.4 billion. R&D spending by the total biopharmaceutical industry grew an estimated 2.3% to $67.4 billion. PhRMA members’ domestic R&D spending rose 5.7% to $37,371.0 million, while foreign spending increased 8.7% to $12,047.4 million. As a percentage of sales, […]
In late April, the NIH released a list of cuts to grant awards in the wake of the final fiscal year 2011 budget. The $30.9 billion allocated to the NIH for fiscal 2011 is almost 1% less than what the agency received in fiscal year 2010. All modular and nonmodular noncompeting research-grant levels from NIH […]
Although mining companies’ profits in 2010 reached an all-time high of more than $50 billion, and the companies are investing to increase their supplies of major raw materials, it probably will not be enough to accommodate strong demand or curb rising commodity prices. Mining companies are increasing capital investment but face numerous obstacles in developing […]
Upon their creation in 2006, induced pluripotent stem (iPS) cells were intended to be a less controversial alternative to stem cells, since they were created in a lab instead of by the destruction of embryos. However, several recent studies have shown them to be a less optimal choice. The iPS cells died faster and were […]
Western oil companies are divesting their refineries after a decades-long slump that has led to prolonged overcapacity and, thus, weak margins. Refining margins, which reached a high of $4.50 a barrel, are now 10% of that and declining, and are expected to remain weak in the future. Weak margins, however, are not discouraging state-owned and […]
The US leads the world in research but is expected to face competition in the future, according to the Royal Society’s 2011 Knowledge, Networks & Nations report. The report used information compiled from an April 2010 survey, a discussion session, interviews, secondary research and data analysis to examine the changing landscape of science and innovation. […]
An agreement, or “continuing resolution,” for the fiscal 2011 budget was reached by President Obama and leaders of the Democratic Senate and Republican House of Representatives. The budget cuts funding for science agencies across the board, but much less so than the initial budget approved by the House of Representatives in February would have. Science […]
Worldwide, finance and investment in the clean energy sector increased 30% in 2010 to reach $243 billion. More than 90% of all clean energy investments were in companies and projects in the Group of Twenty (G-20) leading economies. Europe was the top recipient of clean energy finance at $94.4 billion. Clean energy investments totaled $65.8 […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.

